Prophylactic platelet transfusions are considered as standard in most hematology centers, but there is a long-standing controversy as to whether standard prophylactic platelet transfusions are necessary or whether this strategy could be replaced by a therapeutic transfusion strategy. In 106 consecutive cases of patients receiving 140 autologous peripheral blood stem cell transplantations, we used a therapeutic platelet transfusion protocol when patients were in a clinically stable condition. Platelet transfusions were only used when relevant bleeding occurred (more than petechial). Median duration of thrombocytopenia o20 Â 10 9 /l and o10 Â 10 9 /l was 6 and 3 days, which resulted in a total of 989 and 508 days, respectively. In only 26 out of 140 transplants (19%), we observed clinically relevant bleeding of minor or moderate severity. No severe or lifethreatening bleeding was registered. The median and mean number of single donor platelet transfusions was one per transplant (range 0-18). One-third of all transplants, and 47% after high-dose melphalan could be performed without any platelet transfusion. Compared with a historical control group, we could reduce the number of platelet transfusions by one half. This therapeutic platelet transfusion strategy can be performed safely resulting in a considerable reduction in prophylactic platelet transfusions.
Introduction
There is an increasing demand for single donor platelet transfusions due to intensive chemotherapy and blood stem cell or bone marrow transplantation. Platelet transfusions however are expensive and associated with a number of side effects including febrile or allergic transfusion reactions, transmission of bacterial and viral infections, circulatory congestion, transfusion-related acute lung injury and alloimmunization.
During the last 10 years, it has been clearly shown by several studies that severe thrombocytopenia after intensive chemotherapy for acute myeloid leukemia can be safely managed with a threshold of 10 Â 10 9 /l or even lower for routine prophylactic platelet transfusion. [1] [2] [3] [4] On the basis of these results, three clinical studies were performed with a 10Â 10 9 /l trigger in recipients of high-dose chemotherapy7total body irradiation (TBI), followed by hematopoietic stem cell support. [5] [6] [7] All three studies proved the safety of the 10 Â 10 9 /l trigger for prophylactic platelet transfusion after autologous bone marrow or peripheral blood stem cell transplantation (PBSCT).
A recent survey of transfusion practices at 18 transplant centers in the US and Canada reported that five centers used a threshold for prophylactic platelet transfusion of o10-15 Â 10 9 /l. Most severe bleeding events occurred at platelet counts of greater than 20 Â 10 9 /l and therefore would not have been prevented even using this level as a transfusion trigger. 8 Virtually the same data were reported from an analysis of 1402 bone marrow transplants at Johns Hopkins Hospital. 9 Therefore, the American Society of Clinical Oncology recently published clinical practice guidelines with a prophylactic platelet transfusion trigger of 10 Â 10 9 /l for acute leukemia and hematopoietic cell transplantation. 10 The use of peripheral blood stem cells instead of bone marrow in autologous transplants has substantially shortened the duration of severe thrombocytopenia. It is still not known whether a prophylactic platelet transfusion strategy is necessary, or whether a therapeutic transfusion strategy is as safe and more cost effective. Therefore, we started a prospective study with a new therapeutic platelet transfusion protocol for all consecutive patients after autologous PBSCT beginning in the year 2001.
The main objective of the study was the safety and feasibility of a therapeutic transfusion strategy. The study was approved by the institutional review board of the Hematology/Oncology Department at the Klinikum Nuremberg, Germany.
Patients and methods
Since 2001, a therapeutic platelet transfusion strategy has been offered to all consecutive patients receiving myeloablative high-dose chemotherapy7TBI, followed by autologous PBSCT. Patients with a diagnosis of AL-amyloidosis, documented aspergillus infection, cerebral lesions or life-threatening bleeding complications during prior chemotherapy courses were excluded. All patients gave their informed consent for stem cell transplantation and our transfusion strategy.
Transfusion strategy
Therapeutic platelet transfusions were defined as transfusions to treat a patient with documented clinically relevant bleeding during thrombocytopenia.
Petechias, retinal bleeding without impairment of visus and minimal self-limiting nasal bleeding were not considered as clinically relevant.
In clinically stable patients, no prophylactic platelet transfusions were performed irrespective of the morning platelet count. These patients received only therapeutic platelet transfusions when clinically relevant bleeding was documented. In cases of significant bleeding (according to the World Health Organisation (WHO) grade II or greater), platelets were transfused within 3-4 h.
All platelet transfusions were random single donor apheresis platelets, ABO compatible, with platelet concentrations according to German guidelines of the 'Deutsche Gesellschaft fu¨r Transfusionsmedizin und Immunha¨mato-logie' with 2-5 Â 10 11 platelets/unit. All transfusions were leukocyte-reduced (o10 6 leukocytes). Platelet transfusions were available 24 h a day.
In clinically unstable patients, platelet transfusions were given prophylactically when the morning platelet count was o10 Â 10 9 /l. The definition of a clinically unstable patient was fever 438.51C and/or local infectious infiltrations suspicious for invasive aspergillosis, sepsis syndrome or clinically relevant plasmatic coagulation disorders. In case of surgery and biopsies (except bone marrow), the platelet count should be 420 Â 10 9 /l. Daily morning platelet count was performed until the platelet count was self-supporting and greater than 20 Â 10 9 /l for 2-3 days. Blood counts were performed on EDTA-anticoagulated blood using a hemocytometer (Sysmex SF-3000, Sysmex Corp., Kobe, Japan). The patients were examined twice daily for evidence of hemorrhage. Fundoscopy was performed only in case of impairment of vision.
Hemoglobulin levels were maintained at greater than 80 g/l by packed red cell transfusions.
Infection prophylaxis and treatment
Prophylactic oral antimycotics and antibiotics, as well as the initiation of intravenous antibiotics for fever greater than 38.51C, and the start of intravenous antimycotics were applied according to the German guidelines.
11 Granulocyte colony-stimulating factor was given to all patients on day þ 6 after transplantation until the leukocyte count was above 1 Â 10 9 /l for 3 days. Aspirin and nonsteroidal anti-inflammatory drugs were avoided. Paracetamol and metamizol were used as antipyretics. All patients were hospitalized during the study period.
Bleeding and toxicity
During each therapy course, bleeding complications according to WHO criteria (0, none; I, petechial; II, mild blood loss; III, gross blood loss; IV, debilitating blood loss) were recorded as well as the number of platelet transfusions administered. Clinically relevant bleeding was defined as melena, hematemesis, macrohematuria, hemoptysis, vaginal bleeding, epistaxis with gross blood loss, retinal bleeding with impairment of vision or soft tissue bleeding requiring blood transfusions. The bleeding complications were recorded by the responsible physician. The examination for bleeding was performed twice daily. Bleeding complications were reviewed by one senior physician (HW, KS). Maximal bleeding per transplant was counted. Only fevers greater than 38.51C were documented, as well as the origin of fever and the underlying organisms in case of septicemia. Mucositis was documented according to the Bearman toxicity score. 12 
Statistics
Numbers of transplants without any platelet transfusion in different groups were compared using the w 2 test and frequencies of transfusion between multiple myeloma patients and other diagnoses or between the TBI and non-TBI group were calculated using the Mann-Whitney U-test running on a computer-based program (STATISTICA for Windows, 2001, Statsoft Inc., Tulsa, OK, USA).
Results
The study included 106 consecutive patients with a total number of 140 transplantation procedures. Patients' characteristics are listed in Table 1 . The median age of the patients was 54 years, with a range of 18-70 years. The male to female ratio was about 2:1. The diagnoses were multiple myeloma in 43%, malignant lymphoma in 32% and acute leukemia in 16% of the cases. Only 8% of the patients were transplanted because of a solid tumor. Seventy-six patients received one transplant. In 26 and four patients, respectively, a double or triple transplantation program was performed. The conditioning regimens included chemotherapy and TBI in 19 patients, whereas the other patients received high-dose chemotherapy-based regimens alone. All of these regimens were established myeloablative combination treatments (see Table 1 ).
Bleeding complications
The median number of days with platelets below 20 Â 10 9 /l was 6 (range 0-92) and the median number of days with platelets below 10 Â 10 9 /l was 3 (range 0-62). We observed a total of 989 days with platelets below 20 Â 10 9 /l and 508 days with platelets below 10 Â 10 9 /l. In 114 out of 140 transplants (81%), no clinically relevant bleeding was observed. In 26 transplants (19%), patients experienced maximal bleeding of WHO grade II. WHO grade I (clinically not relevant) was registered in 28 transplants (20%). We observed no bleeding WHO grade III and IV. Bleeding complications of WHO grad II were caused by epistaxis in 12 out of 26 transplants (46%), and Therapeutic platelet transfusion strategy H Wandt et al by mucosal bleeding due to mucositis in eight transplants (30%) ( Table 2 ).
Transfusions
The median and mean number of single donor platelet transfusions was one per transplantation (range 0-18). The median and mean number of therapeutic platelet transfusions per tranplantation was 0 (0-18) and of prophylactic platelet transfusions was 1 (0-13), respectively. Forty-eight out of 140 transplants (34%) could be performed without any platelet transfusion. In patients with normal marrow recovery (o14 days of duration of platelet recovery to 420 Â 10 9 /l), even 42% of all transplants could be performed without any platelet transfusion.
There was a statistically significant difference in the number of platelet transfusions according to diagnosis of the patients, and whether they received a TBI or non-TBI conditioning regimen (Table 3 ). The percentage of transplants without any platelet transfusion between patients with multiple myeloma and other diagnoses was 47 versus 22%, and between patients with non-TBI and TBI regimens 37 and 0%, respectively.
During the study period, a total number of 154 prophylactic and 81 therapeutic platelet units were transfused (see Table 2 ). The main indications for prophylactic platelet transfusions were fever of unknown origin (FUO) in 46% and septicemia with or without mucositis in 20%. Forty-two out of 106 patients were clinically unstable according to our definition and therefore received platelet transfusions prophylactically.
Forty-two out of a total number of 235 transfusions (27%) were given without a clear indication according to the study protocol. This occurred during 16% of all transplant procedures. Mucositis without relevant bleeding was the indication in most (76%) of these transfusions (see Table 2 ). Forty-two out of 106 patients were clinically unstable according to our definition and therefore received platelet transfusions prophylactically.
Major indications for therapeutic platelet transfusions were epistaxis or mucositis with bleeding (76%) for which, however, only 45% of all therapeutic transfusions were needed (see Table 2 ).
There was no difference in the number of platelet units transfused in patients below or above the median age of 54 years (data not shown).
Retrospective analysis
In a retrospective matched pair analysis, we compared the first 60 transplant procedures in this prospective study with 60 historical peripheral blood stem cell transplants that were performed during the year before we started our new strategy. Our former strategy required platelet transfusions routinely at a morning platelet count o10 Â 10 9 /l. Patients were matched for gender, diagnosis and TBI conditioning. The total number of transfused platelet units could be reduced from 237 to 111, the median number of single donor apheresis platelet transfusions per transplant was decreased from 3 to 1 (Table 4) .
Bleeding complications of WHO grade II and III were registered in 20 and 1%, respectively, which was very comparable to the incidence in our study patients. The median number of red blood cell transfusions needed was 2 (range 0-6). This was exactly the same number and range we needed in our study cohort.
Discussion
To our knowledge, this is the first clinical study that replaced standard prophylactic platelet transfusion by a therapeutic transfusion strategy in clinically stable patients after autologous PBSCT regardless of the morning platelet count.
With this prospective study, we could show in 106 patients that our therapeutic platelet transfusion strategy is safe and more cost effective than the standard prophylactic transfusion strategy with the 10 Â 10 9 /l trigger. No severe bleeding (grade III and IV according to the WHO classification) occurred during 140 transplants after highdose chemotherapy7TBI and 508 days of severe thrombocytopenia (o10 Â 10 9 /l). By the use of peripheral blood stem cells, the median duration of severe thrombocytopenia below 10 Â 10 9 /l or 20 Â 10 9 /l was a very short period of 3 and 6 days, respectively. The incidence of minor and moderate bleeding (maximal WHO grade II) was only 19%. This bleeding incidence compares favorably with moderate and severe bleeding events reported in the literature for autologous transplants with a prophylactic platelet transfusion strategy. 5, 6, 8, 9 In the study of Bernstein et al., 8 in patients after autologous PBSCT, only major, severe and life-threatening bleeding was counted (corresponding to bleeding WHO grade III and IV). They reported an incidence of 9%. In the analysis performed with a prophylactic transfusion strategy at Johns Hopkins Hospital, 18.5% moderate and severe bleeding was reported for autologous transplants. 9 This higher incidence of severe bleeding events might be explained by the fact that these transplants were performed with bone marrow leading to a longer duration of leukocytopenia and thrombocytopenia.
The low incidence and severity of clinically relevant bleeding (19% WHO grade II) in our study is the reason why only a minority (34%) of all platelet transfusions was performed for therapeutic purposes. Bleeding events were mainly caused by epistaxis and mucositis (in 76%).
In patients treated with TBI-containing regimens, we observed a more severe mucositis which lead to significantly more transfusions compared with patients after chemotherapy-based regimens alone. Our experience is in accordance with published data of patients with multiple myeloma who were randomized to a TBI and non-TBI regimen. Patients with TBI 8 Gy and melphalan 140 mg/m 2 needed twice the platelet transfusions compared with melphalan 200 mg/m 2 . 13 In 46% of all prophylactic transfusions, fever of unknown origin was the main trigger for transfusion. We did not see an increased bleeding risk in those clinically stable patients with fever. Therefore, we believe that fever per se need not be a trigger for prophylactic platelet transfusion in future transfusion protocols.
In 16% of all transplant procedures, platelet transfusions were not performed in complete accordance with our protocol. Seventy-six percent of these transfusions were given prophylactically for mucositis without bleeding. This experience shows the difficulty for the medical staff to reduce prophylactic platelet transfusions even within a protocol. For further multicenter studies, it is important to educate physicians and nurses to follow strictly the guidelines of the therapeutic transfusion strategy, which was proven to be safe in our study.
Despite 27% of all transfusions being given in violation to the protocol guidelines, we could reduce the number of apheresis platelet transfusions substantially (about one half) by our new transfusion strategy compared to a matched historical control group. Thirty-four percent of all procedures and about half of the transplants for multiple myeloma could be performed without a single platelet transfusion.
A survey in 1991 conducted of institutional members of the American Association of Blood Banks (hospitals) in hematology/oncology patients has shown that about 20% of the hospitals did not administer prophylactic transfusions, but rather used therapeutic platelet transfusions only in response to active bleeding. 14 In 1987, there were only a minority of 5% of leukemia and bone marrow transplant services which did not transfuse platelets prophylactially. 15 However, the hospitals using platelets prophylactically administered twice as many platelet transfusions. Previous studies comparing bleeding risks in patients with leukemia who received therapeutic rather than prophylactic transfusions indicated that bleeding was corrected in all patients. Thus, a therapeutic platelet transfusion policy is a promising approach, but its actual efficacy was unproven because of the small numbers of patients included in these prior studies. [16] [17] [18] There is a long-standing controversy in the scientific community of hematologists and oncologists as to whether standard prophylactic platelet transfusions are necessary or whether this strategy should better be replaced by a therapeutic transfusion strategy. 10, 17, [19] [20] [21] [22] During the last 20 years, the recommendations of the American Society of Clinical Oncology reduced the trigger for prophylactic platelet transfusion from 20 Â 10 9 /l down to 10 Â 10 9 /l for thrombocytopenia following intensive chemotherapy or after hematopoietic stem cell transplantation. 10 The decision to administer platelet transfusions should incorporate individual clinical characteristics of the patient and not simply be a reflex to the morning platelet count. Platelet transfusions are expensive and associated with a number of side effects. Recently Ballen et al. 23 reported autologous stem cell transplantations without the use of blood product support in Jehovah's Witnesses, a religious group that refuses transfusion of any major blood product. Of 26 patients, there was only one lethal cerebral bleeding in a patient with a still active brain medulloblastoma. Another patient had life-threatening gastrointestinal bleeding but the patient recovered after regeneration of platelets. Three other patients had moderate bleeding with epistaxis and/or hematuria. This report supports our therapeutic platelet transfusion strategy since timely platelet transfusion could have corrected all major bleeding events except in the case of the medullablastoma patient. Patients with cerebral infiltrations, however, were excluded from our therapeutic transfusion strategy.
A large prospective randomized trial is needed comparing the new therapeutic platelet transfusion strategy with the standard prophylactic platelet transfusion strategy using a morning trigger of 10 Â 10 9 /l for transfusion. Therefore, we have now started such a multicenter trial in Germany.
